All In Biotech

Drug Trial Radar · NCT04679103

A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)

A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in Patients With Paroxysmal Nocturne Hemoglobinuria, Who Have Been Involved Earlier in the Clinical Trials of Eculizumab

Last checked: Nov 20, 2026Latest source record: Dec 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

50

Actual

Start

May 3, 2018

Primary completion

Apr 20, 2020

Study completion Apr 20, 2020

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A safety and immunogenicity study in long-term treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in patients with paroxysmal nocturnal hemoglobinuria, who have been involved earlier in the clinical trials of Eculizumab (JSC "GENERIUM", Russian Federation).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • Eculizumab (JSC GENERIUM, Russia)Biological

    Eculizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency and severity of adverse events (AEs), serious adverse events (SAEs), including those associated with the use of the study drug.Time frame: 6 months
  2. The number and proportion of patients with antidrug antibodies; titer of antidrug antibodies and their neutralizing activity.Time frame: 6 months
  3. Changes in vital signs during the study.Time frame: 6 months
  4. Changes in physical examination during the study.Time frame: 6 months
  5. Changes in ECG during the study.Time frame: 6 months
  6. Changes in Doppler echocardiography during the study.Time frame: 6 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital"

    Chelyabinsk, Chelyabinsk Oblast, Russia

  • Federal State Budgetary Institution of Science "Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency"

    Kirov, Kirov Oblast, Russia

  • Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov"

    Saint Petersburg, Leningradskaya Oblast', Russia

  • Federal State Budgetary Institution "National Medical Research Center of Hematology" of the Ministry of Health of the Russian Federation

    Moscow, Moscow Oblast, Russia

  • State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin of the Moscow Department of Health

    Moscow, Moscow Oblast, Russia

  • State budgetary institution of health care of the Moscow region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"

    Moscow, Moscow Oblast, Russia

  • State budgetary institution of the Rostov region "Rostov Regional Clinical Hospital"

    Rostov-on-Don, Rostov Oblast, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation

    Samara, Samara Oblast, Russia

  • State Budgetary Healthcare Institution of the Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital No. 1"

    Yekaterinburg, Sverdlovsk Oblast, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.